SKIN The Journal of Cutaneous Medicine

Mark Lebwohl, Linda Stein Gold, Melinda J. Gooderham, Kim A. Papp, Laura K. Ferris, David N. Adam, H. Chih-ho Hong, Leon H. Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham

Page s218

Poster PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, Andrew Blauvelt

Page s219

Poster PDF

Atopic Dermatitis

Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2)

Eric Simpson, Lawrence Eichenfield, Melinda Gooderham, Mercedes E. Gonzalez, Adelaide Hebert, Kim Papp, Vimal H. Prajapati, David Krupa, Patrick Burnett, David Berk, Robert Higham

Page s220

Poster PDF

Alopecia

Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study

Maryanna Senna, Seth Forman, Lindsey Bordone, Pablo De La Cueva Dobao, Robert Wolk, Samuel Zwillich, Fan Zhang, Haytham Mohamed Ahmed, Liza Takiya

Page s224

Poster PDF

Skin Cancer

Combining the 31-gene expression profile test for cutaneous melanoma with the American Joint Committee on Cancer staging identifies the highest-risk patients with stage I-II disease

David Hyams, Jung S. Byun, Brian Martin, Christine N. Bailey, Timothy Stumpf, Valentina I. Petkov

Page s223

Poster PDF

Acne & Rosacea

Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne

Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH

Page s221

Poster PDF

Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne

Linda Stein Gold, MD, Leon H. Kircik, MD, William Philip Werschler, MD, Hilary Baldwin, MD, Valerie Callender, MD, Lawrence Green, MD, Neil Sadick, MD, Jeffrey L. Sugarman, MD, PhD, Zoe D Draelos, MD, Emil A Tanghetti, MD, Neal Bhatia, MD

Page s222

Poster PDF

Nail Unit Disorders

Monthly Usage of Efinaconazole 10% Solution in Two Phase 3 Randomized Trials: Is One 4-mL Bottle Enough for Proper Treatment?

Steven R Feldman, MD, PhD, Tracey C Vlahovic, DPM, Warren S Joseph, DPM, C Ralph Daniel, MD, Boni Elewski, MD, Phoebe Rich, MD, Shari R Lipner, MD, PhD

Page s228

Poster PDF

Seborrheic Dermatitis

Patient and Healthcare Provider Perspectives on the Disease Burden of Seborrheic Dermatitis in the United States: Results From a National Survey

Raj Chovatiya, Lakshi Aldredge, Candrice Heath, Moises Acevedo, David H. Chu, Diane Hanna, Melissa Seal, Matthew Zirwas

Page s225

Poster PDF

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus

Andrew Blauvelt, Zoe D. Draelos, Melinda Gooderham, Edward Lain, Angela Y. Moore, Kim A. Papp, Matthew Zirwas, David Krupa, Patrick Burnett, David R. Berk, David H. Chu

Page s226

Poster PDF

Dermatopharmacology

Dermal Irritation, Sensitization, and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Healthy Participants

Zoe D. Draelos, MD, Emil A. Tanghetti, MD, Linda Stein Gold, MD, Leon H Kircik, MD, Neal Bhatia, MD, Joshua A. Zeichner, MD, Jeffrey L. Sugarman, MD, PhD

Page s227

Poster PDF